Radio drug Azedra for adrenal tumours

September 14, 2018 0 By CH Unnikrishnan

Iobenguane I 131 (Azedra) injection for the treatment of patients with pheochromocytoma or paraganglioma has been approved for sale in US.

Azedra is the first US FDA approved drug for fadults and adolescents of age 12 and older with the rare adrenal tumours that cannot be surgically removed, have spread beyond the original tumour site and require systemic anticancer therapy.

The efficacy of Azedra was shown in a single-arm, open-label, clinical trial in 68 patients, which measured the number of patients who experienced a 50 percent or greater reduction of all antihypertensive medications lasting for at least six months.

A radioactive therapeutic agent, Azedra includes a warning about radiation exposure to patients and family members, which should be minimized while the patient is receiving Azedra. The risk of radiation exposure is greater in pediatric patients.

Azedra, manufactured by Progenics Pharmaceuticals Inc, received Orphan Drug designation.